Clovis Oncology Stock News

The performance of penny stocks continues to be mixed relative to more widely-followed stocks, but if you've looking for the best penny stocks to buy now, this works to your advantage. As has been the

Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).

Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetic

Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. Netcapital Inc. (NASDAQ: NCPL

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Clovis Oncology (NASDAQ: CLVS ) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. The first thing that investors need to know about is Clov

Clovis Oncology Inc. stock CLVS, -9.94% fell 10% in premarket trade Monday, after the biotech filed for Chapter 11 bankruptcy and said it would sell assets. The company has a commitment for up to $75

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) shares rose 18.1% to $0.6316 in pre-market trading after jumping over 34% on Friday. Cosmos Holdings, last month, posted Q3 loss of $0.08 per share. Zhihu

Investors in Clovis Oncology (NASDAQ: CLVS ) stock will want to prepare for a bankruptcy filing following a warning from the pharmaceutical company. According to a filing with the U.S. Securities and

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.